Oxford Biomedica clinches second gene therapy deal – The Times
The Times |
Oxford Biomedica clinches second gene therapy deal
The Times An Oxford University spin-off that specialises in gene therapy applications has won a $100 million contract from Bioverativ, an American company specialising in treatments for haemophilia. Shares in Oxford Biomedica rose 11.7 per cent to 12p after it … |
